Solcitinib;GSK-2586184;GLPG-0778)/ supplier with competitive price in stock-Rechems

Details:

Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Shanghai Rechem science Co., Ltd.
Rechemsis focus on R&D of new APIS, signal transduction inhibitors and pharmaceutical intermediates. We follow closely the industry trend, and the latest research achievements in life science area.
Rechems is located in the largest biomedical base in China--Shanghai and cooperatively established modern production base and laboratory in surrounding areas. We have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research and inventory trading in medicinal chemistry.
Rechems's mission is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
Rechems's vision is to be recognized by our clients as one of the best suppliers of chemical products for our superior quality, efficient and cost-effective services.
We insist the principle of "Quality first, customer foremost, best credit, be pioneering and creative", looking forward to establishing good business relationships with customers all over the world. Let's work together for bright future!